| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Termination of a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities
As previously disclosed in its Current Report on Form 8-K filed on November 10, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement, dated November 10, 2023 (the “Loan Agreement”), with K2 Health... |
| 30 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projec... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Aug. 12, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 16 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2026, Acumen Pharmaceuticals, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals at the Annual Meeting, each of which is described in more deta... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., May 12, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for t... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Mar. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 16 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 13, 2026, by and among Acumen Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreeme... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other proj... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Nov. 12, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 10 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
EXHIBIT 99.1 Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors NEWTON, Mass., Nov. 10, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biophar... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., August 12, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) fo... |
| 15 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other proj... |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Acumen Pharmaceuticals, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., May 13, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for... |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Mar. 27, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) fo... |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Nov. 12, 2024 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) fo... |
| 13 Aug 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Aug. 13, 2024 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) fo... |
Loading...